FDA rejects Summit's China-invented lung cancer drug ivonescimab over survival data
The FDA rejected ivonescimab, a lung cancer drug first developed in China, because its global trial did not show a statistically significant survival benefit.
Key takeaways
- The US Food and Drug Administration rejected ivonescimab, a lung cancer drug invented in China and licensed to Summit Therapeutics. The agency said the global trial did not show a statistically significant survival benefit. The decision is a setback for a drug seen as a test of China's rise in drug development.

Key points
- The FDA rejected ivonescimab, a lung cancer drug first developed in China, because its global trial did not show a statistically significant survival benefit.
- Summit Therapeutics disclosed the rejection in a Sunday news release, and the drug had been seen as a test of China's rise in drug development.
- Summit argues slow patient enrollment explains the survival shortfall, but the FDA was not persuaded by its later analyses.
The US Food and Drug Administration has turned down ivonescimab, a lung cancer drug first developed in China, in a decision Summit Therapeutics disclosed in a news release on Sunday. The setback hits a medicine that had become a symbol of China's growing clout in drug development. Financial Times described the outcome as a blow to Beijing's biotech sector, since the drug was seen as a test of whether a Chinese-made medicine could pass US scrutiny.
Summit, a Florida company, bought the US rights from Akeso Biopharma, the Chinese drugmaker that created the compound in its laboratories and sells it in China. Summit had sought approval only for certain patients with advanced lung cancer. The drug is also being tested in tumours of the colon, bladder and breast, which is why it attracted such high hopes.
The agency's stated reason was that the global trial behind the application had not shown a statistically significant gain in how long patients lived. That study ran in the United States, Canada, Europe and Asia and enrolled patients who had already tried a targeted treatment. Those patients received ivonescimab plus chemotherapy or chemotherapy alone.
In that trial the drug did delay the cancer's progression, but it did not prove a survival benefit. Summit said the FDA told it the drug must show it helps people live longer. The company argues that the failure to extend lives simply reflected slow enrollment in the study. To strengthen its case, Summit sent the agency analyses of longer-term patient outcomes that were not part of the original research plan. Those analyses were not enough to persuade regulators.
Sources: Financial Times, MarketWatch, The New York Times